MedTrace Logo

Manganese-Enhanced Magnetic Resonance Imaging of MyOcardial injuRY in COVID 19 (COVID-19)

NCT04625075 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2024-05-07

No results posted yet for this study

Summary

Our understanding of the clinical manifestations of COVID-19 is growing on a daily basis and there is evidence that increased age, cardiovascular risk factors and cardiac comorbidity are strongly associated with poor outcomes. Furthermore, myocardial injury occurs and is associated with a much worse outcome and rapid increase in mortality. There have been several reports of myocarditis and heart failure following infection. The mechanisms of myocardial injury and its consequences are not well understood.

In an ongoing peer-reviewed and funded study, the investigators are evaluating the use of magnetic resonance imaging (MRI) to characterise and to understand the mechanisms of heart failure and myocarditis. Following strong encouragement by the British Heart Foundation, the investigators now propose to extend this investigation to patients who have recovered from COVID-19 infection to understand the mechanisms of myocardial injury that they have experienced. Using gadolinium and manganese-enhanced MRI combined with Computed tomography coronary angiography (CTCA), the investigators will assess the mechanisms and direct impact of myocardial injury in patients who have recovered from COVID-19 infection. This will help the investigators understand how best to manage individuals who demonstrate evidence of myocardial injury and potentially provide insights that could lead to novel treatment interventions to reduce such injury and improve patient outcomes.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

Cardiac MRI

Cardiac MRI with gadolinium and manganese contrast

DIAGNOSTIC_TEST

Cardiac CT

Cardiac CT to assess coronaries

DIAGNOSTIC_TEST

Electrocardiogram (ECG)

ECG to assess rhythm

DIAGNOSTIC_TEST

Blood samples

renal function liver function full blood count, hematocrit glucose

Sponsors & Collaborators

  • University of Edinburgh

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-10
Primary Completion
2021-06-10
Completion
2022-02-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04625075 on ClinicalTrials.gov